By Fineline Cube 
German pharmaceutical and chemical giant Bayer (ETR: BAYN) released its Q1 2025 financial report, recording revenues of EUR 13.738 billion (USD 15.4 billion), a slight 0.1% year-on-year (YOY) decline. The revenue decrease was primarily attributed to the Crop Science Division’s performance, increased costs from the Group’s Long-Term Incentive (LTI) program, and a EUR 165 million (USD 185 million) negative impact largely due to high inflation.
Pharmaceuticals Division Performance
The Pharmaceuticals Division (Prescription Medicines) achieved a 4.1% increase in sales (currency and portfolio-adjusted) to EUR 4.548 billion (USD 5.09 billion). Notable growth drivers included:
- Nubeqa (darolutamide): Sales rose by 77.5%.
- Kerendia (finerenone): Sales grew by 86.6%.
- Eylea (aflibercept): Sales increased by 4.7%.
The Radiology business also reported growth, driven by higher sales of CT Fluid Delivery and Ultravist. Contraceptive products Mirena and Yaz series saw increases of 18.4% and 14.1%, respectively. However, sales of the oral anticoagulant Xarelto (rivaroxaban) fell by 31.2% due to generic competition, particularly in Europe and Japan.
Consumer Health Division Performance
The Consumer Health Division (Self-Care Products) reported a 2.5% YOY sales increase to EUR 1.499 billion (USD 1.68 billion). Growth was achieved in three of its four global business regions, driven by volume increases in North America and Asia-Pacific. Additional highlights included a 12.7% YOY rise in digestive health product sales and a recovery in U.S. cold and cough product sales. In contrast, the allergy business and Nutritionals category saw declines, with the latter down by 5.2% YOY.-Fineline Info & Tech